Viatris: Low Prices, Low Performance
November 23, 2023
🌧️Trending News
Viatris Inc ($NASDAQ:VTRS) is a pharmaceutical company that specializes in providing generic medicines to its customers at low prices. Although their prices may be attractive, their performance and value are steadily declining. Viatris has been criticized for their lack of innovation, their slow response time for customer service inquiries, and their low-quality products. This has resulted in customers being more hesitant to purchase products from Viatris due to the low value they receive for their money.
In addition, there have been reports of mismanagement within the company, including allegations of a hostile work environment and a lack of transparency in how the company is being run. This has caused customers to further question the company’s ability to provide quality, reliable products. With all these shortcomings, customers are beginning to look elsewhere for a more reliable and trustworthy pharmaceutical provider. Customers are increasingly becoming aware of the issues with the company’s products and services and are choosing to shop elsewhere for their needs. Unless Viatris can demonstrate that they are a reliable and trustworthy partner, its value will continue to decrease.
Share Price
Viatris Inc, a global pharmaceutical company, has seen its stock prices take a dip on Tuesday. Opening at $9.4, the stock closed at the same price, down by 1.0% from the previous closing price of $9.5. This decline comes despite a string of strong performances from the company over the past few months, suggesting that investors may have been expecting better results than the company delivered. With a low stock price and seemingly low performance, it remains to be seen if Viatris Inc can turn things around and increase investor confidence in the coming days. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Viatris Inc. More…
| Total Revenues | Net Income | Net Margin |
| 15.47k | 1.83k | 11.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Viatris Inc. More…
| Operations | Investing | Financing |
| 2.46k | 904.6 | -2.71k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Viatris Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 48.74k | 27.88k | 17.39 |
Key Ratios Snapshot
Some of the financial key ratios for Viatris Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.3% | 1.1% | 20.1% |
| FCF Margin | ROE | ROA |
| 13.1% | 9.3% | 4.0% |
Analysis
GoodWhale has conducted an analysis on the wellbeing of VIATRIS INC, and from our Star Chart we have classified it as a ‘rhino’, suggesting that the company has achieved moderate growth in both revenue and earnings. Such a company may be attractive to a range of different investors, from those looking for short-term gains to those who prefer to invest for the long-term. VIATRIS INC is strong in the areas of dividend, growth, and profitability, but weak when it comes to its asset base. However, despite the weak assets, it still has an impressive health score of 8/10 with regards to its cashflows and debt. This suggests that the company is capable of riding out any crisis it may face without the risk of bankruptcy. More…
Peers
The company has a rich history of more than 150 years, dating back to the founding of its predecessor companies, which include some of the world’s most well-known brands. Today, Viatris is a leading provider of essential medicines and solutions, with a presence in more than 150 countries and a workforce of over 30,000 people. The company’s mission is to provide access to high-quality medicines and solutions for patients and customers around the world. Viatris is committed to being a trusted partner for patients, customers, employees, shareholders, and society. The company’s products are available in a wide range of therapeutic areas, including cardiovascular, diabetes, oncology, respiratory, and other conditions. Viatris has a portfolio of more than 1,000 products, including many that are essential medicines. The company also offers a range of services, including manufacturing, distribution, and logistics, to support its customers and patients. Viatris’s competitors include Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, and other global pharmaceutical companies.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is an American multinational pharmaceutical corporation. It is one of the world’s largest pharmaceutical companies. The company was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company’s headquarters are in New York City. The company’s products include medicines and vaccines for a wide range of medical conditions and diseases.
– Teva Pharmaceutical Industries Ltd ($NYSE:TEVA)
Teva Pharmaceutical Industries Ltd is a pharmaceutical company with a market cap of 9.07B as of 2022 and a Return on Equity of -9.35%. The company focuses on producing generic drugs and active pharmaceutical ingredients. Teva is the world’s largest manufacturer of generic drugs and one of the world’s largest pharmaceutical companies.
– GSK PLC ($LSE:GSK)
GlaxoSmithKline PLC is a British pharmaceutical company with a market capitalization of 58.8 billion pounds as of 2022. The company has a return on equity of 34.04%. GlaxoSmithKline is a global healthcare company that researches, develops, and manufactures pharmaceuticals, vaccines, and consumer healthcare products.
Summary
Viatris Inc. is a stock market investment with a generally low share price. Over time, the value of the stock has been decreasing, which may be concerning for investors. By analyzing the company’s financial statements, investors can identify potential risks and rewards associated with this stock. Additionally, reviewing trends in the company’s business model, evaluating its industry, and studying its competitors can provide more insight into the future potential of Viatris Inc. as a stock market investment.
